CYD-TDV vaccine shows moderate protection against dengue in Asian children The first dengue vaccine candidate to attain phase 3 clinical testing shows moderate protection against the condition in Asian children, according to new research published in The Lancet www.tadalafil-en-belgique.com/generique-ou-marque.html . Dengue is a mosquito-borne disease that infects around 390 million people each year, of whom about 96 million have problems with symptomatic an infection. This stage 3 trial occurred in dengue-endemic areas across five countries in Asia, a region that accounts for over 70 percent of the global dengue burden. The study involved 10 275 healthy children aged 2 to 14 years who had been randomly assigned to receive three shots of the CYD-TDV vaccine or a placebo at 0, 6, and 12 months, and followed for 2 years.5 percent.
Wisconsin: Senate Expenses 352 states that certified first responders can administer the medication if they have received training. The states in which patients don’t have to present a prescription to receive naloxone at our pharmacies allow standing up purchase or collaborative practice agreements between pharmacies and prescribers for this medication, CVS spokesperson Mike DeAngelis told Pharmacy Instances. DeAngelis said CVS is usually hoping to enter similar agreements in various other states, but he did not mention any specific states that the pharmacy chain was pursuing. CVS vice president of pharmacy professional practices Tom Davis, RPh, noted in a press release that increased usage of naloxone might help save sufferers’ lives. Over 44,000 people die from accidental drug overdoses every year in the United States, and most of these deaths are from opioids, including controlled substance pain medication and illegal medications such as for example heroin, Davis stated.